Nasdaq has approved the listing of Canary Capital's Injective ETF on November 4, 2026. The ETF gives INJ its first regulated exchange-traded product in the United States.
The ETF opens a new institutional demand channel for INJ. Traditional investors gain an exchange-traded route to the token through Canary Capital's product, bringing access to INJ into the regulated US securities market.
Cointelegraph@Cointelegraph⚡️ JUST IN: Nasdaq has approved the listing of Canary Capital’s Injective ETF featuring staking rewards. pic.twitter.com/gWczC4K2sn
Nov 04, 2026
⚡️ JUST IN: Nasdaq has approved the listing of Canary Capital’s Injective ETF featuring staking rewards. pic.twitter.com/gWczC4K2sn
